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Nanoparticle-infused-biodegradable-microneedles
as drug-delivery systems: preparation and
characterisation†
Rachel E. Sully, a Hemda Garelick,b Eriketi Z. Loizidou,b Adrian G. Podoleanu *c
and Vladimir Gubala *a
For almost two decades, scientists have been exploring the use of nanoparticles as drug vesicles capable of
protecting their cargo and deliver it to the target site while evading detection by the body. However, their
translation to clinical use has been slower than expected. To a large degree, this is due to the difficulty to
formulate the nanomaterial into a usable form, in which they retain their unique, size-dependent properties
without aggregating into a bulk material. In this work, we describe a simple methodology for synthesising
novel biodegradable microneedle systems infused with silica nanoparticles (SiNP). SiNP were doped with
small library of model anti-cancer drugs or drug surrogates before being characterised and encapsulated
into biodegradable microneedles. Detailed preparation and characterisation methods for both the
nanoparticles and the microneedles-infused with nanoparticles are presented here. We demonstrated the
distribution of the nanoparticles within the microneedle matrix in a uniform, un-aggregated form, which
enabled the release of the nanoparticles in a sustained manner. Formulating nanomaterial into
biodegradable, hydrogel-like microneedles was shown to be effective in preserving their colloidal properties,
whilst simultaneously enabling the transdermal delivery of the nanomaterial into the body. Although the
concepts of nanoparticles and biodegradable microneedles have been researched individually, the
combination of the two, to the best of our knowledge, offers a new pathway to nanomedicine-related
applications.
Introduction
Nanoparticles (NPs) are minute objects between 1–100 nm in
size with three major properties – they are highly mobile in the
free state; have a very large surface area-to-volume ratio; and
may exhibit quantum effects, which influences their electronic
characteristics.1–3 These properties may help them escape the
natural defence mechanisms of the human body.4 There are
many types of nanoparticles which are made from biocompa-
tible and biodegradable materials,5 including polymeric nano-
particles, metallic nanoparticles, magnetic nanoparticles,
inorganic nanoparticles, organic nanoparticles, etc. They have
been shown to present great potential for transportation of
drugs.6–9
Using nanoparticles as drug vesicles provides many advantages,
such as good biocompatibility; protection of the drug molecules;
and specific targeting, to name a few.10,11 The efficiency of drug-
delivery systems is related to their size. Nanoparticles are small in
size with a large surface area, meaning the drug is closer to the
surface and therefore released faster. If they are too large in size, i.e.
over 200 nm, the lymphatic system is activated and the nano-
particles are cleared from the body quicker.10,12
Another characteristic of nanoparticles that influences their
clearance from the body is their surface properties. Targeting
ligands, surface curvature and surface reactivity can be carefully
designed to prevent aggregation, to increase stability and to
influence receptor binding to the nanoparticles.10 The more hydro-
phobic the surface, the more likely the nanoparticle is to be cleared
from the body. To overcome clearance from the body,10,12 their
surfaces can be coated with polymers, however this does not
overcome aggregation. Coating with capping agents or altering
the zeta (z) potential (surface charge) have been reported to tackle
the aggregation problem with more success.10,12
Drug release from nanoparticles is achieved either by erosion
of the matrix, releasing drugs from their interior, producing a
rapid burst of drug release followed by a sustained release; or by
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release of drugs bound to the exterior surface of nano-
particles.5,10,12,13 Once in the blood system, nanoparticles migrate
to their desired target by active or passive targeting. Active
targeting involves conjugating the nanoparticles to a specific
tissue or cell ligand. Whereas, passive targeting involves migrating
to the specific tissue through leaky junctions.10
For nanoparticles to be ideal drug-delivery systems, they
should be able to reach their target, be recognised, bind and
deliver their load to the specific tissue whilst minimising or
avoiding drug induced damage to healthy tissues.
An excellent example of the earlier studies of nanoparticles
used as drug-delivery systems showed the entrapment of anti-
cancer drugs into silica nanoparticles (SiNP) of size 60–70 nm
and wall thickness of 10 nm.14 The release of these drugs was
studied over 12 hours and showed an initial large release within
the first 20 minutes followed by a slow sustained release over
the following 10 hours. From these findings it was concluded
that hollow porous SiNP could be used successfully as drug-
delivery systems.
Some examples of polymeric nanoparticles as drug-delivery
systems were applied for treatment of HIV/AIDS,10 malaria,11
and tuberculosis;5 delivery of insulin12 or of psychotic drugs;11
hormone treatments;11 and many more.11
Although nanoparticles have been shown to be good drug
carriers, their formulation remains to be a major challenge.
They tend to aggregate when in solution due to the effects of
Ostwald Ripening and Brownian motion, where smaller parti-
cles move, dissolve and deposit onto larger particles to form a
thermodynamically stable state.15 Previous research presented
by Giovannini et al.15 showed that entrapping nanoparticles in
hydrogels could represent a very good storage environment for
SiNP, as the dense, hygroscopic matrix of a hydrogel can slow
down any movements of nanoparticles and inhibit any reac-
tions of the silica matrix, thus effectively preventing undesired
aggregation.15
Giovannini et al.15 studied the long-term stability of SiNP
and gold nanoparticles (AuNP) by storing them in both aqueous
solutions and hydrogels for several weeks. The carefully engi-
neered nanoparticles stored in solutions displayed visible
aggregates from as early as one week. However, the nano-
particles in hydrogels were stable and without aggregates for
many weeks or months (as illustrated in Fig. 1). Because the
studied hydrogel was responsive to mechanical forces, the
release of the nanoparticles from the hydrogel was facilitated
by shaking/vortexing of the nanoparticle–hydrogel formulation,
which turned the gel back into an injectable solution. When
this solution was injected into an animal model (i.e. chicken
embryos), we reported on the presence of aggregation, the
cytotoxicity and delivery effects. While this was an elegant
resolution to nanoparticle aggregation, formulation and sto-
rage, our next attempt was to formulate the nanoparticles into a
gel that could have the potential to release and deliver the
nanoparticles directly, without additional manipulation and
changing the phase from gel to a solution.
Therefore, an alternative strategy, exploiting the use of
biodegradable microneedles (MN), as a novel delivery system
for nanoparticles is being introduced in this work. A micro-
needle–nanoparticle-gel formulation would enable the delivery
of nanoparticles directly (i.e. without the need to change the gel
into an injectable solution), while it would be possible to store
the microneedle–nanoparticle-gel formulation for longer time
without risking nanoparticle aggregation. Although there has
been extensive research into the use of nanoparticles as drug
vesicles, the field of microneedles for transdermal drug-delivery
is still in its infancy and there is very little research into the
incorporation of nanoparticles into dissolvable microneedles.
Microneedles have been defined as ‘a canula which is either
solid or hollow with an approximate needle length ranging
between 50–900 mm and an external diameter of around
300 mm’.16 The length and shape of the needle is carefully
engineered so that it painlessly penetrates the stratum cor-
neum and deposits the cargo in the epidermis/dermis interface.
There are many different types of microneedles including solid
microneedles, coated microneedles, hollow microneedles, poly-
mer microneedles, biodegradable/dissolvable microneedles
and hydrogel forming microneedles,17 and the potential of
microneedles for drug delivery applications have been exten-
sively researched.18–23
Fig. 1 Scheme showing the prevention of aggregation of nanoparticles in
gels – (a) nanoparticles in solution; (b) nanoparticles in self-supporting

























































































5434 |  Mater. Adv., 2021, 2, 5432–5442 © 2021 The Author(s). Published by the Royal Society of Chemistry
In this work, we prepared SiNP infused with various model
drugs (e.g., a small library of known anti-cancer agents), drug
surrogate (e.g., fluorescein isothiocyanate (FITC)) and formu-
lated the nanoparticles into biodegradable microneedle gels for
transdermal delivery. The materials used for microneedles in
this project was biodegradable carboxymethyl cellulose (CMC),
mixed with readily available carbohydrates (e.g., maltose,
sucrose, or trehalose). We hypothesised that from a long-term
perspective, incorporating the nanoparticles into a biodegrad-
able polymer not only prevents their aggregation, but also
allows them to be sustainably released into the epidermis,
surpassing the stratum corneum barrier. CMC has been used
as it has been shown to form an anti-aggregation layer,24 which
makes it more useful as a matrix for nanoparticle encapsula-
tion. In addition, microneedles formed from CMC/sugar are
not too brittle and do not break upon insertion into the skin,25
as well as the material being inexpensive and available even for
a potential scale-up production. The SiNP used in this research
were synthesised by a microemulsion method.26 The fabricated
nanoparticles: pristine SiNP; fluorescein isothiocyanate dye-
doped SiNP (FITC-NP); and anti-cancer drug-doped SiNP
(Drug-NP), were characterised using various techniques includ-
ing Dynamic Light Scattering (DLS), Transmission Electron
Microscopy (TEM) and Scanning Electron Microscopy (SEM).
The nanoparticles were incorporated into the microneedle
arrays at varying concentrations, following the synthesis
described by Loizidou et al.25 The nanoparticle-microneedles
were characterised using SEM and imaged by darkfield and
confocal microscopy. Their degradation time and storage
stability were also studied. The optimisation of the microneedle
preparation is also discussed within this paper.
Results and discussion
Synthesis of silica nanoparticles
The synthetic route used to synthesise the SiNP is known as the
microemulsion method and involves dispersing two or more immis-
cible liquids as droplets by stirring. Ammonium hydroxide is used as
a catalyst and ethanol is used to break the microemulsion.26 The
products of this synthetic route appeared to show very uniform
samples (PdI o 0.1) of neatly spherical particles.
DLS was used to study both the pristine SiNP and the FITC-NP,
giving average sizes of 109.41  3.21 nm and 96.09  8.33 nm
respectively (Tables S1–S2, ESI†). These sizes were compared to
those observed by TEM, which were 73.20  6.23 nm for the
pristine SiNP and 84.17  1.18 nm for FITC-NP (Fig. 2a and b).
Often there can be a discrepancy between the size data by DLS and
TEM due to the DLS measuring the hydrodynamic radius of the
nanoparticles in a solution, whereas TEM measures their dia-
meter in vacuum. Depending on what type of nanoparticles are
being observed, as well as their synthetic route, their hydrody-
namic radius varies proportionally with the quantity of water
molecules that their surface attracts.
The surface charge of both types of nanoparticles were also
measured using DLS. Pristine SiNP were slightly less negative than
the FITC-NP, showing an average z-potential of30.178 5.30 mV
compared to37.37 5.03 mV (Tables S1–S2, ESI†). Nanoparticles
with such negative charge tend to be more stable in buffered
Fig. 2 TEM images of nanoparticles (scale bar represents 200 nm for all images) – (a) pristine silica nanoparticles; (b) FITC-doped silica nanoparticles; (c)
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solutions, such as phosphate buffered saline (PBS). We have
previously observed that the colloidal stability of silica nano-
particles stored in aqueous media, such as PBS or cell culture
media ranges typically between 1–4 h.27
Degradation of silica nanoparticles
SiNP are produced by hydrolysis of –Si–OH groups. This reac-
tion is reversible, meaning that in aqueous solution, SiNP can
also disintegrate into smaller fragments. This, in fact, is a
useful feature, the slowly degrading silica matrix is able to
release any cargo into the environment, while at the same time,
when the SiNP degrades into fragments smaller than 5 nm, the
nanoparticle can be renally cleared from the body. In this work,
the degradation of the nanoparticles was studied in both PBS
and in an aqueous solution containing bovine serum albumin
(BSA). FITC-NP enabled us to track the nanoparticle degrada-
tion by monitoring the changes of the fluorescence signal over
time. The fluorescence intensity of the supernatant, is propor-
tional to the concentration of FITC molecules released from the
silica matrix into the solution, thus indicating nanoparticle
degradation. This process was measured by fluorescence micro-
scopy at regular intervals over a period of 72 hours. The plotted
data can be seen in the Fig. S1 and S2 (ESI†). The nanoparticles
began to degrade between 8 and 24 hours in PBS but the
process was slower in a BSA solution, where an observable
degradation was recorded between 48 and 72 hours. This is
presumably due to BSA being adsorbed onto the FITC-NP
surface, slowing down the release of FITC molecules into the
solution. In both cases, the degradation half-life suggests that
nanoparticles may possess the capacity to migrate and target
the desired tumour cells before they begin to degrade and
release their cargo.26
Synthesis of anti-cancer drug-doped silica nanoparticles
In the degradation experiment, FITC was used as a drug-
surrogate in the preparation if the nanoparticles, as it was
relatively easy to visualise the FITC-NP by fluorescence. Encap-
sulation of FITC within SiNP is well studied and the synthesis is
robust and reproducible. However, encapsulating the SiNP with
anti- cancer drugs is not as straightforward as it seems. Four
anti-cancer drugs were chosen to be used in the synthesis
of nanoparticles. Doxorubicin (DOX), temozolomide (TMZ),
5-fluorouracil (5-FU) and paclitaxel (PAC) were selected because
they are all routinely prescribed for patients with cancer and
because their relatively subtle structural differences allowed us
to understand the influence of charge and or functional groups
(i.e. hydrophobicity/hydrophilicity) on the size, shape and
charge of the resulting nanoparticles. The nanoparticles were
doped using solutions with drug at 1-5% (w/w) concentrations,
which equate to critically relevant concentrations stated in
literature,28 and the changes in size and surface charge
between the different samples were observed using DLS and
TEM. Average sizes ranged from B162–184 nm by DLS (Tables
S4–S7, ESI†) and B39–56 nm by TEM (Fig. 2 and Table S8,
ESI†). The discrepancy between these results implies that the
drug–NP have large hydrodynamic radii, suggesting that they
could potentially form a large protein corona when in plasma.
A protein corona is a phenomenon that occurs when nano-
particles come into contact with protein-rich media such as
blood or plasma. The nanoparticles become covered in proteins
which significantly impacts on their size, charge, aggregation
Fig. 3 Concentrations of anti-cancer drugs encapsulated into silica nanoparticles – this data shows a general increase in concentration as initial mass
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and how quickly they are cleared from the systemic circula-
tion.2 The average surface charges (Tables S4–S8, ESI†) for the
drug–NP was 32 mV, which is similar to that of the pristine
SiNP (30 mV), suggesting that incorporating molecules into
nanoparticles can have some influence on their surface
properties.
The concentration of the drug, in mg of the drug per 1 mL of
nanoparticles, expressed as a loading efficiency, was measured
by UV/Vis absorbance. Calibration curves (Fig. S3–S6, ESI†) for
each anti-cancer drug in ethanol were plotted and used to
extrapolate the mass of the drugs within the nanoparticles,
which was then used to calculate the loading efficiency of the
nanoparticles using equation 1.




The results are displayed in Fig. 3. The data shows trends
between the change in initial mass of the drug used in the
synthesis and the concentration of the drug that becomes encap-
sulated inside the drug–NP. DOX shows no specific trend and very
little drug encapsulation, which could be due to the large size of
the drug molecule itself. Whereas, the smaller drug molecules,
TMZ and 5-FU, show good encapsulation efficiency. PAC shows
good encapsulation for the initial 1% and 2% (w/w) concen-
tration, however above these percentages, the encapsulation
concentration decreases again, this may be due to the extremely
large size of paclitaxel molecules leading to lower encapsulation
due to limited space within the SiNP core. Previous investigations
into doping nanoparticles with paclitaxel29 have also discussed
the effect of steric hindrance, which is defined as the steric effect
arising from crowding of substituents,30 causing maximum drug
loading. For the drug–NP to be synthesised reproducibly and with
predictable physico-chemical properties, a fine balance between
the organic phase, aqueous phase and the surfactant must be
maintained. The presented data indicate that this balance can be
influenced by the initial mass of the drug used in the synthesis, as
well as by the intrinsic properties of the drug itself. While all the
tested drugs have limited water solubility, TMZ and 5-FU are
structurally more similar than the bulkier DOX and PAC. The
encapsulation efficiencies for the smaller TM and 5-FU were also
following a more similar trend, when compared to the seemingly
random trends for DOX and PAC. The drug–NP synthesis for all
four drugs was performed with multiple replicates, at each initial
mass concentration of the drug. The fact that the standard
deviation for each sample (expressed as error bars in Fig. 3) is
generally high, simply illustrates that while it is possible to
prepare nanoparticles doped with the anti-cancer drugs as shown
in this study, the range of the clinically relevant drug concentra-
tions is relatively broad and does not follow a very clear, pre-
determined pattern. However, examples from the literature
showed that it is possible to fine-tune this microemulsion process
to enable encapsulation of poorly soluble drugs using organically
modified silica matrices.31
Synthesis of microneedle arrays
Microneedle arrays from Carboxymethylcellulose (CMC), com-
bined with either Trehalose (TRD), Sucrose (SUC) or Maltose
(MAL), each one at 50% (w/w) concentration were successfully
synthesised with and without nanoparticles incorporated into
them. Their stability was studied over 30 days at room tem-
perature and 4 1C both quantitatively and qualitatively. No
change in mass or appearance was observed over a long period
of time, thus suggesting that the arrays are stable, presumably
suitable for medicinal use or for transport if needed for any
other research purposes.
The standard procedure to prepare microneedle arrays with
nanoparticles incorporated inside them requires a 72 hour-long
evaporation step at atmospheric pressure, during which the
CMC/TRD (or CMC/SUC or CMC/MAL) solution solidifies into a
hydrogel matrix. We found out that most of the nanoparticles
could aggregate within the 72 hours (unpublished data) before
the material solidifies into a hydrogel. Therefore, we have
modified the standard procedure to avoid or minimise the risk
of nanoparticle aggregation. To this end, we have fabricated the
nanoparticle-microneedles at decreased pressures in order to
speed up the evaporation process, thus keeping the nano-
particles in solution for as short time as possible. The pressures
used were over the range of 100–400 mBar at 100 mBar
intervals. The low pressure drastically accelerated the evapora-
tion time to 3–4 hours instead of 72 hours.
Initially, we attempted to prepare the microneedles in a
vacuum oven, which would enable us to control the tempera-
ture as well. However, the microneedles are formed on a
silicone mould, which needs to be evacuated before the CMC/
sugar/nanoparticle solution is poured over it. Placing the
mould in vacuum ensures that the solution fills completely
all the needle-cavities and forms a very uniform, microneedle
array when the solution solidifies and is peeled off the mould.
Because the vacuum oven had to be opened and exposed to an
atmospheric pressure to allow the solution to be deposited over
the mould, we observed the formation of bubbles in the
microneedle array. The set up was therefore changed. A simple,
wide-neck vacuum flask with rubber septum was employed to
hold the mould. Once the flask with the mould was evacuated,
the solution was poured over the mould via septum using a
syringe, while maintaining the vacuum inside the flask.
Although this might appear trivial, the optimisation of the
protocol was critical for us to produce high quality microneedle
arrays with infused nanoparticles, in a reproducible and robust
way (Fig. 4).
Characterisation of microneedle arrays
With the optimised vacuum protocol, FITC-NP were incorporated
into the microneedle arrays in order to characterise the FITC-NP-
microneedles and observe the distribution of the nanoparticles
inside of the microneedle arrays. Various microscopy techniques
were used to image and locate the nanoparticles, including
darkfield microscopy, fluorescence microscopy, confocal micro-
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overall fluorescence image of the arrays. While the individual
microneedles were clearly visible, which offered very useful infor-
mation about their size and shape, the resolution of this technique
did not allow to identify the exact position of the nanoparticles
inside the needles. Both fluorescence microscopy and confocal
microscopy were used to form z-stack 3D images which again
showed very clearly the shape and size of the individual micro-
needles; however, the fluorescence intensity maps could not pin-
point the spatial distribution of the nanoparticles inside the
microneedles (Fig. 5i and ii). Therefore, we have prepared another
set of microneedles with incorporated commercial gold
nanoparticles (with diameter and surface charge similar to that
of FITC-NP) and observed them using back-scattered SEM. The
images presented in Fig. S11–S13 (ESI†) demonstrated mostly
unaggregated gold nanoparticles, uniformly distributed within
the microneedle matrix. The mechanical properties of the micro-
needle arrays without nanoparticles have been extensively studied
in a previous work.32 That work involved a combination of experi-
mental and finite element analyses which showed that micronee-
dles made of CMC/MAL are superior to those made of CMC/TRD
and CMC/SUC in terms of mechanical strength. Buckling was
predicted to be the main mode of microneedle failure and the
order of buckling was positively correlated to the Young’s modulus
values of the sugar constituents of each microneedle. Furthermore,
in the same study it was identified that small changes (i.e., less than
10% change) to the sugar formulation are unlikely to affect the
overall mechanical properties of the microneedles. Similar results
have been observed in this project when investigating the effect of
nanoparticle presence on gelation time and morphology. SEM
imaging showed no changes in morphology between biodegradable
gels fabricated with or without silica nanoparticles at varying
pressures. Minimal differences in gelation time between gels with
and without nanoparticles encapsulated confirm that the presence
of nanoparticles does not alter the mechanical properties of
the microneedle arrays. This data can be found in Fig. S25 and
Table S11 (ESI†).
The ability of the prepared microneedle arrays to penetrate
through the skin layers was qualitatively demonstrated on an
ex vivo model, using skin of 6 weeks old nude mice. 1  1 cm
square piece of mouse skin was cut and a CMC-TRD micro-
needle array was gently pressed into the skin. The sample was
then mounted in the sample holder and images taken by a
Fig. 4 CMC-MAL microneedle array structure consisting of 324 needles
of height 750 mm, base diameter 200 mm, tip diameter 10 mm and centre-
to-centre spacing of 600 mm.
Fig. 5 (i) Confocal microscopy image of FITC-NP encapsulated into CMC-MAL array; (ii) backscattered SEM images of CMC-MAL microneedle array
with AuNP incorporated into the matrix – (a) microneedle array with AuNP; (b) single needle of microneedle array with AuNPs incorporated showing an
isolated cluster of AuNP on the tip of the needle; (c) backing plate of microneedle array with AuNP showing some aggregated AuNP and some single
AuNPs distributed; (iii) optical coherence tomography image of biodegradable microneedle array in mouse skin demonstrating the ability of these arrays
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non-invasive technique for cross-sectional tissue imaging,
called Optical Coherence Tomography (OCT). OCT uses light in
the near-infrared spectral range, with a penetration depth of
several hundred micrometres in tissue. The backscattered light
is measured to reconstruct the depth profile of the sample, as
clearly demonstrated on Fig. 5iii. This image clearly shows a
penetration of the microneedle array through the stratum
corneum and into the epidermis/dermis interface layer of the
nude mice skin. The microneedles did not appear to be bend-
ing or breaking upon the contact with the skin, which is a good
indication of the applicability of the studied concept to deliver
nanomaterial via a transdermal route.
Aggregation of nanoparticles in solution and in microneedle
arrays
Nanoparticle aggregation in solution is one of the major
obstacles when translating the results from laboratory bench
into a commercial product. A classic example of nanoparticle
aggregation, which typically results in precipitation of the
nanomaterial is shown in Fig. S14 (ESI†). The aggregation
timeframe depends on the type of nanomaterial and its intrin-
sic properties such as the size, surface chemistry and surface
charge. Nonetheless, silica-based nanomaterial tends to aggre-
gate in aqueous solutions within a few hours. If SiNP are stored
in high salt solution, the aggregation typically occurs within a
few minutes. To compare the effect of solution vs microneedle
gel, we have formulated FITC-NP both into a brine solution and
a brine-hydrogel (i.e. both formulations inserted in saturated
NaCl solution). When FITC-NP were placed in the brine
solution, we were able to track the aggregation process by
fluorescence, measuring the presence of nanoparticles from
the top layer of the solution. Over time, the FITC-NP aggregated
and precipitated to the bottom of the vial. We measured the
fluorescence in the top part of the vial. As demonstrated in
Fig. S15 (ESI†), the nanoparticle fluorescence kept decreasing
over time, indicating fast aggregation and nanoparticle preci-
pitation. For comparison, we have also formulated the FITC-NP
into a hydrogel and immersed it into a brine solution (Fig. S16,
ESI†). We tracked the movement and precipitation of the FITC-
NP by image analysis software. Fig. S17 (ESI†) shows that the
position of FITC-NP did not dramatically change over the same
period of time. The hydrogel prevented the FITC-NP from
moving inside the matrix, thus inhibited the nanoparticle
aggregation. In line with our previously published data,4 we
have confirmed that the FITC-SiNP were stable in the hydrogel
matrix for at least 4 hours (Fig. S18 and S19, ESI†). This is in
stark contrast with the same nanoparticles stored in brine
solution, where a visible aggregation was observed in just
15 minutes.
Degradation of microneedle arrays
The prerequisite for the dissolvable microneedles to be used as
efficient formulation to deliver drugs into a body is that the
individual needles, once inserted into the epidermis, degrade
over time and release the nanoparticles with their cargo. The
degradation of the different FITC-NP-microneedle arrays was
performed over 72 hours in either a solution of PBS or a
solution containing tyrosinase, an enzyme that is present in
our skin, normally responsible for skin pigmentation abnorm-
alities. Tyrosinase is however also known to play role in
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oxidation of and degradation of various carbohydrates33–35 which
is why we aimed to employ it to understand its function in the
degradation of the sugar-based, dissolvable microneedles.
The results summarised in Fig. S20 (ESI†) were surprising.
The FITC-NP–microneedle arrays immersed in PBS released
their FITC-NP faster than those immersed in the solution with
tyrosinase. The results were normalised to 10 mg of the
material due to the difference in the microneedle array mass
at the beginning of the experiment. The control data (Fig. S21,
ESI†) also showed that the FITC-NP immersed in PBS (without
the microneedles) degraded faster than FITC-NP immersed in
the tyrosinase solution within the first 24 hours. Therefore, we
continued with the degradation study of the FITC-NP-micro-
needle arrays in PBS only.
The degradation of microneedles, measured as the release of
the FITC molecules from the FITC-NP–hydrogel matrix, was
done over 4 hours (Fig. 6). As before, the results were again
normalised to 10 mg of the material. The results showed that
the FITC-NP in microneedle arrays degraded slower than those
in the solutions. The sugar solutions also showed a greater
intensity throughout the experiment than the FITC-NP only in
PBS. Therefore, the calibration curves of FITC alone and FITC-
NP were studied to investigate if their concentrations effected
the fluorescence intensity (Fig. S22–S24, ESI†). The release of
FITC from the FITC-NP was also studied to understand whether
the maximum amount of FITC had been released from the
nanoparticles over the four hours of degradation.
The calibration curve of FITC in PBS and ethanol (90% v/v :
10% v/v) showed the fluorescence intensity of FITC is directly
proportional to the concentration of FITC. However, the calibration
curve for FITC-NP in PBS showed the fluorescence intensity initially
decreased at lower concentrations before proportionally increasing
with higher concentrations. This can be attributed to a homo-FRET
effect of two adjacent FITC molecules (i.e. self-quenching). The self-
quenching phenomenon is caused by the re-emission of absorbed
energy from molecules in the excited state. As self-quenching
occurs, these molecules dissipate energy between the ground state
and excited state, resulting in a state with reduced fluorescence
intensity in comparison to molecules that are not self-quenching.
There are many ways to overcome the self-quenching effect of dye
molecules, including the optimisation of dye molecules concen-
tration within the nanoparticles.36
The results of the FITC release from FITC-NP were used to
calculate the percentage release of FITC from the microneedle
arrays. This study showed that the results from the 4 hour
degradation study for the microneedle arrays support that only
the FITC-NP (39.88% from CMC-TRD arrays; 42.38% from
CMC-SUC arrays; and 30.27% from CMC-MAL arrays) were
released from the microneedle arrays, due to the very low
percentage release of FITC (26.44%), and that the FITC-NP
were not degraded themselves. This supports the conclusion
that the microneedle arrays release the FITC-NP in a sustained
manner, showing a very gradual release between 0–2 hours and
then more significant release between 2–4 hours, without
affecting the nanoparticle vesicle itself. This holds promise
that ligand-coated nanoparticles could be released from the
microneedle arrays and target the cancer cells before the
nanoparticles degrade.
Conclusions
The work presented here demonstrated a useful step-by-step
strategy to produce biodegradable, dissolvable microneedle
arrays, infused with SiNP. We showed that SiNP can be success-
fully prepared to hold a variety of anti-cancer drug molecules,
albeit the synthetic procedure for DOX and TMZ should be
further optimised. The aggregation studies on FITC-NP and
AuNP in different microneedle matrix, showed no observable
aggregation of nanoparticles in the microneedle arrays when
imaged by confocal microscopy and SEM respectively. The
degradation of the microneedle arrays displayed a sustained
release of FITC-NP, without disintegration of the nanoparticle
and thus without the premature release of the cargo. Nano-
particles as drug delivery concepts have been a subject of
intense studies for the past 20 years, yet without significant
commercial and/or clinical success. Formulation of the mate-
rial that is intended to be used as the next generation of
nanomedicine still remains a challenge. We believe that the
work presented in this article represents a significant step
towards the development of painless drug delivery systems, in
which the carefully designed nanomaterial can be stored and
applied at any time, while retaining its unique, size-dependant
physico-chemical and biological properties.
Experimental section
Materials
The following chemicals were purchased from Sigma Aldrich:
fluorescein isothiocyanate (FITC) (90%); (3-aminopropyl)trimetho-
xysilane (APTMS) (97%); methanol (anhydrous, 99.8%); tetraethyl
orthosilicate (TEOS) (trace metal basis, 99.999%); ammonium hydro-
xide (28% NH3 in water, 99.99%); 1-hexanol (anhydrous, 99%);
cyclohexane (anhydrous, 99.5%); Tritont X-100 (laboratory grade);
3-(trihydroxysilyl)propyl methylphosphonate, monosodium salt
solution (THPMP) (50 wt% in H2O); phosphate buffered saline
(PBS) tablets; bovine serum albumin (BSA) (pH 7, 98%); 5-fluo-
rouracil (99%); carboxymethylcellulose sodium salt (CMC) (medium
viscosity); D-(+)-maltose monohydrate (MAL) (from potato, 99%);
D-(+)-trehalose dehydrate (TRD) (from saccharomyces cerevisiae,
99%); sucrose (SUC) (BioXtra, 99.5%); N-(3-dimethylaminopropyl)-
N0-ethylcarbodiimide hydrochloride (EDC) (purum, Z98.0%);
poly(amidoamine) (PAMAM) dendrimer (ethylenediamine core, gen-
eration 3.5 solution, 10 wt% in methanol); 2-(N-morpholino)
ethanesulfonic acid (MES) (low moisture content, Z99%).
The following chemicals were purchased from Fisher Scien-
tific: ethanol (absolute, 99.8%); doxorubicin hydrochloride
(BioReagent); paclitaxel (95%); Alexa Flour 647 Goat Anti-
Rabbit IgG (H + L) (2 mg mL1); hydrochloric acid (32% extra
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The following chemicals were purchased from Tokyo
Chemical Industries (TCI): temozolomide (98%); N-hydroxysul-
fosuccinimide sodium salt (NHS) (498.0%).
The animal models were purchased from Charles River as
CD-1 Nude Mice Homozygous Nu/Nu Strain 086 at 6 weeks
of age.
The following instruments were used for characterisation:
 Dynamic light scattering (DLS) – Malvern Panalytical
Zetasizer Nano Series Nano-ZS.
 Transmission electron microscopy (TEM) – JEOL 1230
Gatan One View.
 Tecan Infinite M200Pro Plate Reader.
 WPA Biowave II UV-Vis Spectrometer.
 Scanning electron microscopy (SEM) – Hitachi High Tech-
nologies SU8030 (Tokyo, Japan).
 Olympus BX40 with Transmitted Darkfield Condenser.
 ThorLabs Ganymedet Series Spectral Domain OCT Ima-
ging System.
Experimental
Synthesis of silica nanoparticles
This synthetic method was adapted from Moore et al.26 and was
followed to prepare pristine SiNP, FITC-doped SiNP and anti-
cancer drug-doped SiNP. Briefly, APTMS (5.6 mL; 0.0321 mmol)
was stirred in 1-hexanol (2 mL) for 2 hours. For the preparation
of the FITC-doped SiNP or anti-cancer drug-doped SiNP the
FITC or one of four anti-cancer drugs at different w/w% (see
Table S3, ESI†) respectively, were also added to this solution
before stirring. After 2 hours, 0.666 mL of this solution was
mixed with cyclohexane (7.5 mL), 1-hexanol (1.133 mL), Triton
X-100 (1.77 mL; 2.93 mmol) and deionised (DI) water (0.48 mL)
under vigorous stirring. Immediately after, TEOS (100 mL;
0.451 mol) was added, followed by ammonium hydroxide
(40 mL; 28% (v/v)) 30 minutes later. This mixture was left to
stir for 24 hours before subsequently adding TEOS (50 mL;
0.226 mol). After 30 minutes, THPMP (40 mL; 0.2103 mmol) was
added and 5 minutes later APTMS (10 mL; 0.0573 mmol) before
being left to stir for a further 24 hours. The microemulsion was
then broken through the addition of ethanol (30 mL) before
purifying the nanoparticles with ethanol (3  30 mL) by
centrifugation (7800 rpm for 20 mins). The size and
z-potential of the particles were determined by DLS. The
synthesised nanoparticles were observed using TEM with an
accelerating voltage of 80 kV and a beam amplitude of 15.4 mA.
Degradation of FITC-doped silica nanoparticles
Nanoparticle solutions of concentration 1 mg mL1 were placed
in an Eppendorf tube and centrifuged (14 000 rpm for 5 mins).
The ethanol was removed and replaced with 1 mL of either PBS
(pH = 7.4), BSA (pH = 6.3) or tyrosinase. 100 mL of the surfactant
was removed and measured under fluorescence. The remaining
solution was placed in an incubator at 37 1C taking fluores-
cence measurements of the supernatant at regular intervals.
Absorbance of anti-cancer drug-doped nanoparticles
The absorbance of the different drug-doped nanoparticles was
observed using the Biowave II UV-Vis Spectrometer. The differ-
ent nanoparticles, all at a concentration of 0.1 mg mL1, were
dispersed in ethanol before running absorbance scans from
200–900 nm. TEOS was also combined with ethanol and run as
a control. Each drug alone was dissolved in ethanol at concen-
trations of 0.1–1 mg mL1 and their absorbance determined to
plot a calibration curve. The concentrations of anti-cancer
drugs within the nanoparticles were calculated from the cali-
bration curves displayed in Fig. S3–S6 (ESI†).
Synthesis of microneedle arrays
The protocol for synthesising the microneedle arrays was
from Loizidou et al.25 and was used to prepare plain micro-
needle arrays and nanoparticle-infused microneedle arrays.
Briefly, microneedle arrays consisting of CMC (50 w/w%) and
either TRD (50 w/w%), SUC (50 w/w%) or MAL (50 w/w%)
were prepared by dissolving in DI water under stirring. For
the nanoparticle-infused microneedle arrays, either FITC-NP
or Dox-NPs were added at a concentration of 0.1 mg mL1
during stirring. 200 mL of the gel solutions were then injected
onto an inverted cone shaped silicone micromould under
vacuum. The micromould array consisted of 324 needles of
height 750 mm, base diameter 200 mm and centre-to-centre
spacing of 600 mm. Once the sugar solutions had been
applied, the vacuum was released and the micromoulds were
left to dehydrate in a fumehood at room temperature for
three days.
Synthesis of microneedle arrays at various pressures
Microneedle arrays consisting of CMC (50 w/w%) and either
TRD (50 w/w%), SUC (50 w/w%) or MAL (50 w/w%) were
prepared by injecting 200 mL of the gel solutions (of CMC and
sugars in DI water) onto an inverted cone shaped silicone
micromould. They were then placed in a vacuum oven at
33 1C at various pressures of 100 mBar, 200 mBar, 300 mBar
or 400 mBar to dehydrate. This was also carried out using gel
solutions with nanoparticles-infused in them.
Optical coherence tomography imaging of microneedle arrays
Microneedle arrays were imaged in situ using optical coherence
tomography. The mouse skin was prepared by euthanising
CD-1 Nude Mice Homozygous Nu/Nu Strain 086 at 6 weeks of
age (purchased from Charles River) and removing their skin
from the main body of the mice. The parameters of the
ThorLabs imaging system are as follows: superluminescent
diode source at 930 nm wavelength with a 100 nm tuning
range; an axial resolution of 5.5 mm.
The sample was prepared for imaging by cutting a 1  1 cm
square piece of mouse skin and pressing the CMC-TRD micro-
needle array into the skin. The sample was then mounted in the
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Degradation of microneedle arrays with FITC-NP encapsulated
in PBS and tyrosinase
Microneedle arrays synthesised from each sugar with FITC-NP
encapsulated were placed into the wells of a 24-well plate.
These were covered with PBS only or PBS with tyrosinase and
incubated at 37 1C for 72 hours. 50 mL aliquots were taken at
regular time intervals and the fluorescence intensity measured
(lexc = 488 nm and lemm = 525 nm). Controls of FITC-NP in PBS;
FITC-NP in PBS & tyrosinase; and tyrosinase in PBS were also
studied.
Degradation of microneedle arrays with FITC-NP encapsulated
in PBS
Microneedle arrays synthesised from each sugar with FITC-NP
encapsulated were placed into the wells of a 24-well plate.
These were covered with PBS only and incubated at 37 1C for
4 hours. 50 mL aliquots were taken at half hour time intervals
and the fluorescence intensity measured (lexc = 488 nm and
lemm = 525 nm). Controls of FITC-NP and the sugar solutions
before gelation were also studied.
Calibration curves of FITC and FITC-NP
Various concentrations of FITC and FITC-NP were dissolved in
PBS and ethanol (90% v/v : 10% v/v) or PBS only. The fluorescence
intensity for each concentration was measured at lexc = 488 nm
and lemm = 525 nm. These intensities were plotted against the
concentration to give calibration curves.
FITC release from FITC-NPs
FITC-NP (100 mL; 0.1 mg mL1) were stirred with 10 mL of 10%
sodium carbonate solution (in DI water) for one hour at 1200 rpm.
The pH was then adjusted back to pH 7.4 with hydrochloric acid,
before measuring the fluorescence intensity (lexc = 488 nm and
lemm = 525 nm) of the released FITC.
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